Dirk Schadendorf Google Scholar: h-index, Total Citations, and Citation Map
Dirk Schadendorf's h-index is 193 (1021 i10-index, 253,630+ total citations across 1,000+ publications) according to Google Scholar as of October 2026. Dirk Schadendorf is affiliated with Professor für Dermatologie, University Hospital Essen; University of Duisburg-Essen.
Dirk Schadendorf is a researcher affiliated with Professor für Dermatologie, University Hospital Essen; University of Duisburg-Essen, specializing in Cancer, melanoma, translational research. Their work has been cited 253,630 times. This profile visualizes their global influence, highlighting strong citation networks in United States.
Dirk Schadendorf's Citation Metrics
Bibliometric impact based on 1,000 indexed publications.
- H-Index
- 193
- i10-Index
- 1021
- Total Citations
- 253,630
- Citing Countries
- 89
As of October 2026.
Dirk Schadendorf has an h-index of 193 and 253,630 total citations across 1000 publications, with research cited by institutions in 89 countries.
Download Exports (PNG, CSV, Poster)
Free Viewing Dirk Schadendorf's citation map is always free. Pay once to download poster, PNG, and CSV files for offline use or your visa packet.
Global Impact Map
Visualizing the geographic distribution of institutions that have cited your work.
Starting…
Pins will appear here as institutions are resolved — no need to refresh.
Improved survival with ipilimumab in patients with metastatic melanoma
201019,273
Top Citing Countries
Top Citing Institutions
Visa Evidence Package
Views and exports tuned for EB-1A, O-1A, and EB-2 NIW petitions. Sustained acclaim, geographic reach, and independent-citation filtering are the strongest evidence categories immigration adjudicators look for.
Significant Contributions
Auto-detected research lines — a seminal paper and the follow-up work building on it. Review and edit before using in a petition. Each Free PDF opens in a new tab — EB-1A organises this into the structure USCIS applies to Criterion 5 of 8 CFR § 204.5(h)(3)(v); EB-1B re-frames it under § 204.5(i)(3) (outstanding researcher); NIW presents it under prong 2 of Matter of Dhanasar.
627 citing papers could not be classified (no author data) — excluded from the percentages above.
The researcher established the clinical efficacy of combined nivolumab and ipilimumab therapy for untreated melanoma, a finding validated through long-term outcomes and comprehensive reviews.
The researcher advanced melanoma treatment standards by establishing temozolomide's clinical utility and contributing to the validation of targeted BRAF inhibition, as evidenced by highly cited, independent scholarly uptake.
The researcher advanced melanoma immunotherapy by publishing a seminal NEJM study on nivolumab and extending its application to complex cases with hematological malignancies.
Citation trend (last 10 years)Click to expand
Citation Trend (Last 10 Years)
Related Guides
Learn how to use citation maps for your research and visa applications.
About Dirk Schadendorf's research
Dirk Schadendorf is a researcher in Cancer, melanoma and translational research at Professor für Dermatologie, University Hospital Essen; University of Duisburg-Essen. Their work has been cited 253,630 times across 1,000 publications (h-index 193), according to Google Scholar.
Their most-cited work, “Improved survival with ipilimumab in patients with metastatic melanoma” (2010), has accumulated 19,273 citations. Other influential works include “Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma” (2015) with 10,371 citations and “Improved survival with vemurafenib in melanoma with BRAF V600E mutation” (2011) with 9,944 citations.
Citations of Dirk Schadendorf's research come primarily from United States, China and United Kingdom, reflecting international research impact across 5+ countries. The interactive citation map above shows the full geographic distribution of the institutions citing this work.
